文献速递头颈部肿瘤放疗中枢神经肿瘤放疗姑息放疗与转移瘤

鼻咽癌根治性放疗后长期随访中第二头颈部神经内分泌癌的病理与基因组表型

Pathological and genomic phenotype of second neuroendocrine carcinoma during long-term follow-up after radical radiotherapy for nasopharyngeal carcinoma.
PubMed 文献 · Radiat Oncol · 2021-10-11

该研究收集近三年5例鼻咽癌根治性放疗后发生的第二头颈部神经内分泌癌病例,分析临床病理资料并用高通量二代测序进行基因组分析。结果显示第二NEC预后差,常见突变基因包括TP53、RB1等,涉及p53、MAPK、PI3K-Akt等信号通路,为首次揭示该病的突变图谱。

要点

  • 鼻咽癌放疗后第二头颈部NEC间隔10-18年,预后差。
  • 常见突变基因包括TP53、RB1、NOTCH2等,涉及多条信号通路。
  • 最佳治疗模式尚需未来临床试验探索。

核心结论

  • 第二头颈部神经内分泌癌预后差,本研究首次揭示了其突变图谱、高频体细胞突变及潜在信号通路。

研究设计与样本

  • 收集近三年5例鼻咽癌根治性放疗后第二头颈部NEC病例,获取临床病理资料和图像,采用高通量二代测序进行基因组分析,并用STRING数据库对高频突变基因进行KEGG通路富集分析。

主要发现

  • 所有患者病理诊断为第二NEC,鼻咽癌诊断至NEC诊断间隔10至18年。
  • 2例患者在NEC诊断后3个月和9个月分别出现脑或肝转移。
  • 3例患者死于该病,总生存时间3至9个月。
  • 第二头颈部NEC中常见突变基因(50%)包括TP53、RB1、NOTCH2、PTEN、POLG、KMT2C、U2AF1、EPPK1、ELAC2、DAXX、COL22A1和ABL1。
  • 这些遗传改变可能影响p53信号、MAPK信号、PI3K-Akt信号、鞘脂信号和神经营养因子信号通路。

临床怎么用

  • 对于鼻咽癌放疗后长期随访患者,需警惕第二头颈部NEC的发生。
  • 第二头颈部NEC预后差,治疗决策应综合考虑其侵袭性。
  • 基因组分析发现的突变基因和信号通路可能为未来靶向治疗提供线索。

局限性

  • 样本量小(5例),结论需更大样本验证。
  • 最佳治疗模式尚未确定,需未来临床试验研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Second head and neck neuroendocrine carcinoma (NEC) after radical radiotherapy for nasopharyngeal carcinoma (NPC) treatment is rarely reported. The prognosis of second cancer is poor, and our research focuses on finding a breakthrough in the treatment. In this study, we aimed to investigate clinicopathological characteristics and to identify the genomic landscape of second head and neck NECs. METHODS: We collected five second head and neck NEC cases in the recent three years from our patient database. Clinicopathological data and images were obtained. Genomic analysis was performed using high-throughput second generation sequencing. KEGG pathway enrichment analyses between high-frequency mutations were performed using the STRING database. RESULTS: All patients had been diagnosed with second NEC, according to the pathological observations. The interval between diagnosis of NPC and NEC ranged from 10 to 18 years. Two patients had brain or liver metastasis at three and nine months, respectively, after the diagnosis of NEC. Three patients died of the disease with the overall survival time ranging from three to nine months. Commonly altered genes (50%) in second head and neck NECs included TP53, RB1, NOTCH2, PTEN, POLG, KMT2C, U2AF1, EPPK1, ELAC2, DAXX, COL22A1, and ABL1. Those genetic lesions might affect p53 signaling, MAPK signaling, PI3K-Akt signaling, sphingolipid signaling, and neurotrophin signaling pathways. CONCLUSIONS: Second head and neck NECs had poor prognosis. We revealed, for the first time, the mutational landscape, high-frequency somatic mutations, and potential signaling pathways of second head and neck NECs. Its optimal treatment model needs to be further studied in future clinical trials.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Peng YP, Liu QD, Lin YJ, et al. Pathological and genomic phenotype of second neuroendocrine carcinoma during long-term follow-up after radical radiotherapy for nasopharyngeal carcinoma. Radiat Oncol. 2021. PMID: 34635145. doi:10.1186/s13014-021-01898-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。